SCHEMBL3016062

SCHEMBL3016062

O=S(=O)(c1ccccc1Cl)C1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPK1 P28482 2/20 0.55
SMN1; SMN2 Q16637 4/20 0.53
AR P10275 3/20 0.53
TP53 P04637 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
RAB9A P51151 6/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NPC1 O15118 4/20 0.50
MAPT P10636 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
CTSS P25774 2/20 0.49
FFAR2 O15552 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019657 0.94 MAPT (0.56) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3019121 0.93 LMNA (0.52) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3004717 0.92 SMN1; SMN2 (0.58) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3014009 0.91 SMN1; SMN2 (0.53) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3007135 0.89 MAPK1 (0.54) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3008325 0.89 RAB9A (0.52) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3016150 0.89 AR (0.56) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3011222 0.89 LMNA (0.51) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3001759 0.89 MAPT (0.61) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3014477 0.89 SMN1; SMN2 (0.52) LMNAMEN1KMT2AMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.